You are here

A Long-Term Anti-Malaria Drug-Releasing Implant

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-19-C-0050
Agency Tracking Number: A18B-022-0057
Amount: $149,833.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: A18B-T022
Solicitation Number: 18.B
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2018-12-19
Award End Date (Contract End Date): 2019-06-19
Small Business Information
United States
DUNS: 796010411
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Jason Forte
 Principal Investigator
 (978) 856-4120
Business Contact
 Collette E Jolliffe
Phone: (978) 250-4200
Research Institution
 Iowa State University
 Dr. Balaji Narasimhan Dr. Balaji Narasimhan
2035 Sweeney Hall
Ames, IA 50011
United States

 (515) 294-8019
 Nonprofit College or University

The U.S. Army routinely deploys personnel in malaria-endemic regions as part of normal operations. Preventative measures to malaria infection include a highly-effective daily oral prophylactic antibiotic which is provided to personnel prior to deployment. However, due to side effects including nausea and photosensitivity coupled with organizational culture, poor adherence to the prescribed regimen is common. The U.S. Army seeks the development of a novel polymer implant that can be loaded with FDA-approved malarial chemoprophylaxis antibiotics. This implant should be implanted subcutaneously and release its antibiotic payload into the surrounding tissue through dissolution-controlled diffusion resulting in passive tissue absorption to maintain a steady prophylactic blood level for up to 12 months. This solution will provide safe and non-toxic delivery of doxycycline or Malarone to the affected personnel with demonstrated zero-order release kinetics. Furthermore, initial technology development will enable feasibility studies of scaled-up manufacturing for subsequent testing and marketability. Phase II efforts will focus on developing a working prototype, validating the prototype efficacy using pre-clinical animal models, and developing packaging and application components to augment use at a Role 3 facility. This innovative technology will provide a rapid improvement in malaria prophylaxis for U.S. Army personnel.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government